FDx Advisors’s Emergent Biosolutions EBS Stock Holding History

FDx Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,023	Closed	-$254K	–	807
2019 Q1	$254K	Sell	5,023 -4,954	-50%	-$292K	0.01%	655
2018 Q4	$591K	Buy	9,977 +184	+2%	+$11.9K	0.05%	271
2018 Q3	$645K	Sell	9,793 -1,130	-10%	-$65.9K	0.02%	451
2018 Q2	$552K	Sell	10,923 -13,863	-56%	-$722K	0.02%	511
2018 Q1	$1.3M	Buy	24,786 +11,245	+83%	+$560K	0.04%	423
2017 Q4	$629K	Buy	+13,541	New	+$570K	0.02%	709

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

FDx Advisors's EBS Position: Q2 2019 in Review

FDx Advisors sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 5,023 shares — an estimated $254K sold.

FDx Advisors first reported a position in EBS in Q4 2017 and held it in 6 quarters. The position peaked at $1.3M in Q1 2018. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

FDx Advisors reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
FDx Advisors sold 5,023 Emergent Biosolutions shares in Q2 2019, an estimated $254K.
FDx Advisors first reported a position in Emergent Biosolutions in Q4 2017 and held it in 6 quarters.
FDx Advisors's Emergent Biosolutions position peaked at $1.3M in Q1 2018.
233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on FDx Advisors's 13F filing for Q2 2019, filed 19 Jul 2019.